Tirzepatide
Weight Management | Glycemic Control | Cardiovascular Health | Neuroprotection
Tirzepatide is a groundbreaking dual-incretin mimetic that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, amplifying the body’s natural metabolic regulation. As the active ingredient in the revolutionary therapy Mounjaro, Tirzepatide has redefined treatment paradigms for diabetes and obesity. Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks, rivaling the outcomes of bariatric surgery, alongside a 2.0–2.4% reduction in HbA1c, achieving glycemic control unparalleled in current diabetes treatments (1, 2, 3). By mirroring and enhancing natural physiological processes, Tirzepatide enables a transformative shift toward metabolic balance, inspiring confidence in its potential to elevate both health and quality of life (4, 5).
*Only the lyophilized product is provided.
Weight Management | Glycemic Control | Cardiovascular Health | Neuroprotection
Tirzepatide is a groundbreaking dual-incretin mimetic that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, amplifying the body’s natural metabolic regulation. As the active ingredient in the revolutionary therapy Mounjaro, Tirzepatide has redefined treatment paradigms for diabetes and obesity. Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks, rivaling the outcomes of bariatric surgery, alongside a 2.0–2.4% reduction in HbA1c, achieving glycemic control unparalleled in current diabetes treatments (1, 2, 3). By mirroring and enhancing natural physiological processes, Tirzepatide enables a transformative shift toward metabolic balance, inspiring confidence in its potential to elevate both health and quality of life (4, 5).
*Only the lyophilized product is provided.
Weight Management | Glycemic Control | Cardiovascular Health | Neuroprotection
Tirzepatide is a groundbreaking dual-incretin mimetic that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, amplifying the body’s natural metabolic regulation. As the active ingredient in the revolutionary therapy Mounjaro, Tirzepatide has redefined treatment paradigms for diabetes and obesity. Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks, rivaling the outcomes of bariatric surgery, alongside a 2.0–2.4% reduction in HbA1c, achieving glycemic control unparalleled in current diabetes treatments (1, 2, 3). By mirroring and enhancing natural physiological processes, Tirzepatide enables a transformative shift toward metabolic balance, inspiring confidence in its potential to elevate both health and quality of life (4, 5).
*Only the lyophilized product is provided.
Research Insights
1. Glycemic Control
Tirzepatide achieved HbA1c reductions of 2.0–2.4% in the SURPASS trials, with 91% of patients reaching HbA1c levels <7% (1, 2).
It preserves pancreatic beta-cell function, offering long-term benefits in Type 2 diabetes management (3).
2. Weight Management
Participants in the SURMOUNT trials experienced up to 22.5% total body weight reduction over 72 weeks, far exceeding results from existing GLP-1 therapies (2).
The combination of appetite suppression, delayed gastric emptying, and enhanced metabolic efficiency drives these outcomes (4).
3. Cardiovascular Benefits
Early studies reveal reductions in systolic blood pressure, LDL cholesterol, and C-reactive protein, markers critical to cardiovascular health (4, 5).
Tirzepatide has shown potential to improve left ventricular function and reduce long-term cardiovascular risks (5).
4. Neuroprotection
Preclinical research suggests Tirzepatide mitigates amyloid-beta plaque formation, slows cognitive decline, and promotes neuronal survival, offering potential benefits in Alzheimer’s disease (6).
5. Non-Alcoholic Fatty Liver Disease (NAFLD)
Tirzepatide demonstrated a significant reduction in hepatic fat content and liver inflammation, underscoring its potential in treating NAFLD and NASH (5).
Description & Pharmacodynamics
Tirzepatide’s dual mechanism of action enables synergistic activation of GIP and GLP-1 pathways, targeting critical metabolic functions:
GIP Receptor Activation (1, 3):
Enhances insulin sensitivity and secretion.
Improves lipid metabolism, reducing postprandial triglycerides and cholesterol levels.
GLP-1 Receptor Activation (2, 4):
Promotes glucose-dependent insulin secretion.
Suppresses glucagon secretion, reducing hepatic glucose output.
Reduces appetite via central nervous system pathways and slows gastric emptying.
This combination leads to sustained glycemic control, substantial weight loss, and systemic benefits, including cardiovascular and neuroprotective effects (3, 5).
Pharmacokinetics
Tirzepatide features structural modifications that extend its half-life (~5 days), enabling once-weekly dosing for optimal bioavailability and patient adherence (1).
Structure
Sequence: Synthetic 39-amino acid polypeptide optimized for dual receptor activity.
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813.5 g/mol
PubChem CID: 147200515
Citations
Glycemic Control
Frias, J. P., et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes. Lancet Diabetes & Endocrinology, 2021.
Jastreboff, A. M., et al. Tirzepatide for Glycemic Control and Weight Loss. New Engl J Med, 2022.
Weight Management
Nauck, M. A., et al. Dual Incretin Receptor Agonists and Obesity Therapy. Diabetes Care, 2022.
Cardiovascular Benefits
Rosenstock, J., et al. Effects of Tirzepatide on Cardiovascular Risk Markers. JAMA, 2022.
Neuroprotection
Drucker, D. J. Incretin Hormones and Cognitive Preservation. Nature Reviews Endocrinology, 2020.
NAFLD and Liver Health
Newsome, P. N., et al. Emerging Therapies for NAFLD and NASH: Focus on Tirzepatide. Hepatology, 2021.
